Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Cephalon
Spectrum Pharmaceuticals, Inc
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:
NCT01234766
First received: October 6, 2010
Last updated: May 4, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2020
  Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)